Generic name: fludarabine phosphate
Dosage form: tablet, film coated
This dosage information does not include all the information needed to use Oforta safely and effectively. See full prescribing information for Oforta.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Chronic Lymphocytic Leukemia (CLL)
The oral dose of Oforta™ is different than the intravenous fludarabine phosphate dose.
The recommended adult dose of Oforta™ is 40 mg/m2 administered by mouth daily for five consecutive days. Each 5-day course of treatment should commence every 28 days. Dosage may be decreased or delayed based on evidence of hematologic or nonhematologic toxicity. Physicians should consider delaying or discontinuing the drug if neurotoxicity occurs. Oforta™ can be taken either on an empty stomach or with food. The tablets have to be swallowed whole with water; they should not be chewed or broken.
The following table provides guidance for determining the number of tablets of Oforta™ to be administered based on body surface area (BSA):
|Body Surface Area (BSA)||Calculated Total Dose Equivalent to 40 mg/m2 BSA (rounded up or down to nearest 10 mg)||Total Number of Tablets|
|0.75 – 0.88||30 mg||3|
|0.89 – 1.13||40 mg||4|
|1.14 – 1.38||50 mg||5|
|1.39 – 1.63||60 mg||6|
|1.64 – 1.88||70 mg||7|
|1.89 – 2.13||80 mg||8|
|2.14 – 2.38||90 mg||9|
|2.39 – 2.50||100 mg||10|
A number of clinical settings may predispose to increased toxicity from Oforta™. These include advanced age, renal insufficiency, and bone marrow impairment. Such patients should be monitored closely for excessive toxicity and the dose modified accordingly. The optimal duration of treatment has not been clearly established. It is recommended that three additional cycles of Oforta™ be administered following the achievement of a maximal response and then the drug should be discontinued.